Asset Details
Do you wish to reserve the book?
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines
Do you wish to request the book?
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines
2021
Overview
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known as system x
c
−
. Using a combination of well-defined genetically engineered tumor cell lines and canonical small molecule ferroptosis inhibitors, we now provide unequivocal evidence that sorafenib does not induce ferroptosis in a series of tumor cell lines unlike the cognate system x
c
−
inhibitors sulfasalazine and erastin. We further show that only a subset of tumor cells dies by ferroptosis upon sulfasalazine and erastin treatment, implying that certain cell lines appear to be resistant to system x
c
−
inhibition, while others undergo ferroptosis-independent cell death. From these findings, we conclude that sorafenib does not qualify as a
bona fide
ferroptosis inducer and that ferroptosis induced by system x
c
−
inhibitors can only be achieved in a fraction of tumor cell lines despite robust expression of SLC7A11, the substrate-specific subunit of system x
c
−
.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
